Reduced GSK-3β mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients

Journal of Neural Transmission

Volumn 111, Issue 12, 2004, Pages 1583-1592

  Kozlovsky, N ^a   Shanon Weickert, C ^b   Tomaskovic Crook, E ^b   Kleinman, J E ^b   Belmaker, R H ^a   Agam, G ^a,c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c MENTAL HEALTH CENTER   (Israel)

Author keywords

Glycogen Synthase Kinase (GSK) 3; mRNA; Schizophrenia

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA;

ADULT; ARTICLE; AUTOPSY; BIPOLAR DISORDER; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AUTOPSY; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 11244349108     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0166-3     Document Type: Article

References (40)

1. Akbarian S, Kim JJ, Potkin SG, et al. (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52: 258-266
2. Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3beta. J Biol Chem 8: 8
3. Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R (1993) Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol Psychiatry 34: 529-535
4. Bunney WE, Bunney BG (2000) Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev 31: 138-146
5. Burden SJ (2000) Wnts as retrograde signals for axon and growth cone differentiation [comment]. Cell 100: 495-497
6. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96: 8745-8750
7. Chen G, Huang LD, Jiang YM, Manji HK (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330
8. Cotter D, Kerwin R, Doshi B, Martin CS, Everall IP (1997) Alterations in hippocampal non-phosphorylated MAP2 protein expression in schizophrenia. Brain Res 765: 238-246
9. Dean B, Hussain T (2001) Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia. Schizophr Res 52: 107-114
10. Dean B, Hussain T, Hayes W, et al. (1999) Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 72: 1593-1599
11. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131-137
12. Garcia-Perez J, Avila J, Diaz-Nido J (1998) Implication of cyclin-dependent kinases and glycogen synthase kinase 3 in the phosphorylation of microtubule-associated protein 1B in developing neuronal cells. J Neurosci Res 52: 445-452
13. Harrison PJ, Eastwood SL (2001) Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 11: 508-519
14. Ikonomov OC, Manji HK (1999) Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry 156: 1506-1514
15. Jordan BK, Mohammed M, Ching ST, et al. (2001) Up-regulation of WNT-4 signaling and dosage-sensitive sex reversal in humans. Am J Hum Genet 68: 1102-1109
16. Koch A, Waha A, Tonn JC, et al. (2001) Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93: 445-449
17. Kozlovsky N, Belmaker RH, Agam G (2000) Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157: 831-833
18. Kozlovsky N, Belmaker RH, Agam G (2001) Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 52: 101-105
19. Kozlovsky N, Belmaker RH, Agam G (2002) GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 12: 13-25
20. Kozlovsky N, Nadri C, Belmaker RH, Agam G (2003) Lack of effect of mood stabilizers or neuroleptics on GSK-3β protein levels and GSK-3 activity. Int J Neuropsychopharmacol 6: 117-120
21. Lau KF, Miller CC, Anderton BH, Shaw PC (1999a) Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 54: 85-91
22. Lau KF, Miller CC, Anderton BH, Shaw PC (1999b) Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics 60: 121-128
23. Lucas JJ, Hernandez F, Avila J (1999) Nuclear localization of beta-catenin in adult mouse thalamus correlates with low levels of GSK-3beta. Neuroreport 10: 2699-2703
24. Mackie K, Sorkin BC, Nairn AC, Greengard P, Edelman GM, Cunningham BA (1989) Identification of two protein kinases that phosphorylate the neural cell-adhesion molecule, N-CAM. J Neurosci 9: 1883-1896
25. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G (1999) Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 60 [Suppl 2]: 27-39; discussion 40-1, 113-116
26. Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12: 501-527
27. Moon RT, Brown JD, Torres M (1997) WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 13: 157-162
28. Murray RM (1994) Neurodevelopmental schizophrenia: the rediscovery of dementia praecox. Br J Psychiatry [Suppl]: 6-12
29. Nemanov L, Ebstein RP, Belmaker RH, Osher Y, Agam G (1999) Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. Int J Neuropsychopharmacol 2: 25-29
30. Pap M, Cooper G (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932
31. Patapoutian A, Reichardt L (2000) Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol 10: 392-399
32. Pei JJ, Braak E, Braak H, et al. (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019
33. Ragano-Caracciolo M, Berlin WK, Miller MW, Hanover JA (1998) Nuclear glycogen and glycogen synthase kinase 3. Biochem Biophys Res Commun 249: 422-427
34. Sakanaka C, Sun TQ, Williams LT (2000) New steps in the Wnt/beta-catenin signal transduction pathway. Rec Prog Horm Res 55: 225-236
35. Shaw PC, Davies AF, Lau KF, Garcia-Barcelo M, Waye MM, Lovestone S, Miller CC, Anderton BH (1998) Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome 41: 720-727
36. Torrey EF, Webster M, Knable M, Johnston N, Yolken R (2000) The stanley foundation brain collection and neuropathology consortium [in process citation]. Schizophr Res 44: 151-155
37. Vawter MP, Cannon-Spoor HE, Hemperly JJ, et al. (1998) Abnormal expression of cell recognition molecules in schizophrenia. Exp Neurol 149: 424-432
38. Weickert CS, Webster MJ, Hyde TM, et al. (2001) Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cereb Cortex 11: 136-147
39. Weinberger DR (1996) On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 14: 1S-11S
40. Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J 9: 2431-2438